[144] Rocket Pharmaceuticals, Inc. SEC Filing
Rocket Pharmaceuticals (RCKT) Form 144 notice shows an insider plans to sell 805 shares of common stock through Fidelity on 08/19/2025. The shares were acquired on 08/15/2025 by restricted stock vesting and paid as compensation. The filing discloses prior sales by Jonathan Schwartz: 801 shares on 05/20/2025 for $5,163.25, 11,161 shares on 08/14/2025 for $33,691.71, and 1,680 shares on 08/18/2025 for $5,149.54. The notice includes the required representation that the signer is unaware of undisclosed material adverse information.
Rocket Pharmaceuticals (RCKT) - Una nota Form 144 indica che un insider prevede di vendere 805 azioni di azioni ordinarie tramite Fidelity il 19/08/2025. Le azioni sono state acquisite il 15/08/2025 tramite vesting di azioni soggette a restrizioni e sono state corrisposte come compenso. Il deposito rivela vendite precedenti di Jonathan Schwartz: 801 azioni il 20/05/2025 per $5.163,25, 11.161 azioni il 14/08/2025 per $33.691,71, e 1.680 azioni il 18/08/2025 per $5.149,54. La notifica include la dichiarazione richiesta che il firmatario non 猫 a conoscenza di informazioni materiali avverse non divulgate.
Rocket Pharmaceuticals (RCKT) - Un aviso Form 144 muestra que un insider planea vender 805 acciones de capital com煤n a trav茅s de Fidelity el 19/08/2025. Las acciones se adquirieron el 15/08/2025 por vesting de acciones restringidas y se entregaron como 肠辞尘辫别苍蝉补肠颈贸苍. La presentaci贸n revela ventas previas de Jonathan Schwartz: 801 acciones el 20/05/2025 por $5,163.25, 11,161 acciones el 14/08/2025 por $33,691.71, y 1,680 acciones el 18/08/2025 por $5,149.54. El aviso incluye la representaci贸n requerida de que el firmante no conoce informaci贸n adversa material no divulgada.
Rocket Pharmaceuticals (RCKT) - Form 144 瓿奠嫓鞐� 霐半ゴ氅� 雮措秬鞛愱皜 2025-08-19鞐� Fidelity毳� 韱淀暣 氤错喌欤� 805欤�毳� 毵る弰頃� 瓿勴殟鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 2025-08-15鞐� 鞝滍暅攵� 欤检嫕鞚� 氩犾姢韺�鞙茧 旆摑霅橃棃鞙茧┌ 氤挫儊鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 Jonathan Schwartz鞚� 鞚挫爠 毵る弰 雮挫棴鞚� 瓿店皽霅橃柎 鞛堨姷雼堧嫟: 801欤� (2025-05-20) 毵り皝鞎� $5,163.25, 11,161欤� (2025-08-14) 毵り皝鞎� $33,691.71, 氚� 1,680欤� (2025-08-18) 毵り皝鞎� $5,149.54. 瓿奠鞐愲姅 靹滊獏鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戩殧頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 頃勳垬 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Rocket Pharmaceuticals (RCKT) - Un avis Form 144 indique qu'un initi茅 pr茅voit de vendre 805 actions ordinaires via Fidelity le 19/08/2025. Les actions ont 茅t茅 acquises le 15/08/2025 par vesting d'actions restreintes et vers茅es en tant que 谤茅尘耻苍茅谤补迟颈辞苍. Le d茅p么t r茅v猫le des ventes ant茅rieures de Jonathan Schwartz : 801 actions le 20/05/2025 pour 5 163,25 $, 11 161 actions le 14/08/2025 pour 33 691,71 $, et 1 680 actions le 18/08/2025 pour 5 149,54 $. L'avis contient la d茅claration requise selon laquelle le signataire n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es.
Rocket Pharmaceuticals (RCKT) - Eine Form-144-Mitteilung zeigt, dass ein Insider plant, am 19.08.2025 眉ber Fidelity 805 Aktien des Stammkapitals zu verkaufen. Die Aktien wurden am 15.08.2025 durch Vesting eingeschr盲nkter Aktien erworben und als 痴别谤驳眉迟耻苍驳 ausgezahlt. Die Einreichung nennt fr眉here Verk盲ufe von Jonathan Schwartz: 801 Aktien am 20.05.2025 蹿眉谤 $5.163,25, 11.161 Aktien am 14.08.2025 蹿眉谤 $33.691,71, und 1.680 Aktien am 18.08.2025 蹿眉谤 $5.149,54. Die Mitteilung enth盲lt die erforderliche Zusicherung, dass der Unterzeichner keine nicht offengelegten, wesentlichen nachteiligen Informationen kenne.
- Clear disclosure of the planned sale date, broker, and number of shares (805) provides transparency
- Acquisition source stated as restricted stock vesting, clarifying the reason for ownership
- Prior sales fully reported with dates and gross proceeds, supporting regulatory compliance
- None.
Insights
TL;DR: Routine insider sale notice for recently vested shares; disclosed prior transactions increase transparency but are small versus outstanding shares.
The Form 144 documents a proposed sale of 805 shares acquired through restricted stock vesting and intended to be executed on 08/19/2025 via Fidelity. Prior reported disposals total 13,642 shares across May and August 2025 with aggregate gross proceeds of approximately $44,004. The filing supplies standard certifications about material nonpublic information. Relative to the reported outstanding share count of 107,903,871, these transactions are de minimis and appear procedural rather than material to valuation.
TL;DR: Disclosure is compliant and timely; vesting-origin of shares signals compensation-related liquidity rather than policy breaches.
The notice identifies the securities as compensation from restricted stock vesting dated 08/15/2025 and confirms the signer鈥檚 legal attestation regarding undisclosed material information. The inclusion of multiple recent sale entries and broker details demonstrates adherence to Rule 144 disclosure practices. There is no statement in the filing indicating any governance or compliance concerns.
Rocket Pharmaceuticals (RCKT) - Una nota Form 144 indica che un insider prevede di vendere 805 azioni di azioni ordinarie tramite Fidelity il 19/08/2025. Le azioni sono state acquisite il 15/08/2025 tramite vesting di azioni soggette a restrizioni e sono state corrisposte come compenso. Il deposito rivela vendite precedenti di Jonathan Schwartz: 801 azioni il 20/05/2025 per $5.163,25, 11.161 azioni il 14/08/2025 per $33.691,71, e 1.680 azioni il 18/08/2025 per $5.149,54. La notifica include la dichiarazione richiesta che il firmatario non 猫 a conoscenza di informazioni materiali avverse non divulgate.
Rocket Pharmaceuticals (RCKT) - Un aviso Form 144 muestra que un insider planea vender 805 acciones de capital com煤n a trav茅s de Fidelity el 19/08/2025. Las acciones se adquirieron el 15/08/2025 por vesting de acciones restringidas y se entregaron como 肠辞尘辫别苍蝉补肠颈贸苍. La presentaci贸n revela ventas previas de Jonathan Schwartz: 801 acciones el 20/05/2025 por $5,163.25, 11,161 acciones el 14/08/2025 por $33,691.71, y 1,680 acciones el 18/08/2025 por $5,149.54. El aviso incluye la representaci贸n requerida de que el firmante no conoce informaci贸n adversa material no divulgada.
Rocket Pharmaceuticals (RCKT) - Form 144 瓿奠嫓鞐� 霐半ゴ氅� 雮措秬鞛愱皜 2025-08-19鞐� Fidelity毳� 韱淀暣 氤错喌欤� 805欤�毳� 毵る弰頃� 瓿勴殟鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 2025-08-15鞐� 鞝滍暅攵� 欤检嫕鞚� 氩犾姢韺�鞙茧 旆摑霅橃棃鞙茧┌ 氤挫儊鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 Jonathan Schwartz鞚� 鞚挫爠 毵る弰 雮挫棴鞚� 瓿店皽霅橃柎 鞛堨姷雼堧嫟: 801欤� (2025-05-20) 毵り皝鞎� $5,163.25, 11,161欤� (2025-08-14) 毵り皝鞎� $33,691.71, 氚� 1,680欤� (2025-08-18) 毵り皝鞎� $5,149.54. 瓿奠鞐愲姅 靹滊獏鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戩殧頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 頃勳垬 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Rocket Pharmaceuticals (RCKT) - Un avis Form 144 indique qu'un initi茅 pr茅voit de vendre 805 actions ordinaires via Fidelity le 19/08/2025. Les actions ont 茅t茅 acquises le 15/08/2025 par vesting d'actions restreintes et vers茅es en tant que 谤茅尘耻苍茅谤补迟颈辞苍. Le d茅p么t r茅v猫le des ventes ant茅rieures de Jonathan Schwartz : 801 actions le 20/05/2025 pour 5 163,25 $, 11 161 actions le 14/08/2025 pour 33 691,71 $, et 1 680 actions le 18/08/2025 pour 5 149,54 $. L'avis contient la d茅claration requise selon laquelle le signataire n'a pas connaissance d'informations d茅favorables importantes non divulgu茅es.
Rocket Pharmaceuticals (RCKT) - Eine Form-144-Mitteilung zeigt, dass ein Insider plant, am 19.08.2025 眉ber Fidelity 805 Aktien des Stammkapitals zu verkaufen. Die Aktien wurden am 15.08.2025 durch Vesting eingeschr盲nkter Aktien erworben und als 痴别谤驳眉迟耻苍驳 ausgezahlt. Die Einreichung nennt fr眉here Verk盲ufe von Jonathan Schwartz: 801 Aktien am 20.05.2025 蹿眉谤 $5.163,25, 11.161 Aktien am 14.08.2025 蹿眉谤 $33.691,71, und 1.680 Aktien am 18.08.2025 蹿眉谤 $5.149,54. Die Mitteilung enth盲lt die erforderliche Zusicherung, dass der Unterzeichner keine nicht offengelegten, wesentlichen nachteiligen Informationen kenne.
FAQ
What shares of RCKT are proposed for sale in this Form 144?
How were the 805 shares acquired according to the filing?
What prior insider sales are disclosed in this filing?
Does the filing state any undisclosed material information about Rocket Pharmaceuticals?
What broker is handling the proposed sale?
